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 PROJECT ABSTRACT  The  serotonin  (5‐HT)  neurotransmitter  system  has  been  implicated  in  the pathogenesis of major depression (Blier et al., 1990; Czesak et al., 2006; Lemonde et 
al.,  2003;  Stockmeier  et  al.,  1998).  This  system  can  be  investigated  in  vivo  via Positron  Emission  Tomography  (PET),  a  nuclear  imaging  technology  that  uses radioactively  labeled  molecules  (i.e.  radioligands)  to  quantify  and  visualize biological  processes,  such  as  blood  flow,  brain  metabolism,  and  distribution  of proteins  throughout  the  body.  In  investigations  related  to  depression  specifically, PET is used for measuring in vivo the closest quantification to in vitro concentration of available receptors of the serotonin system (i.e. the binding potential, BPF) (Innis 
et al., 2007). By  using  PET,  investigators  found  higher  serotonin  1A  (5‐HT1A)  binding potential  in  subjects  affected  by  major  depressive  disorder  (MDD)  (Parsey  et  al., 2006; Parsey et al., 2010), suggesting that this is a biologic trait of MDD. Preliminary data also suggest the same abnormality (i.e. higher 5‐HT1A binding)  in healthy (i.e. not  affected  by  mood  disorder)  offspring  of  MDD  subjects,  indicating  familial transmission. It has been observed that MDD aggregates in families and the risk to develop MDD for relatives of depressive subjects (11%‐18%) is significantly greater than  the  risk  for  relatives  of  healthy  controls  (HC)  (0.7%‐7%) (http://www.nimh.nih.gov/research/genetics.htm).  The  ability  to  identify  the population  at  highest  risk  for  developing  MDD  could  help  target  potential preventive interventions and would further our understanding of the pathogenesis of depression, especially in adolescents and young adults. Unfortunately, mental  health  professionals  currently  do  not  have  objective tools  to  classify  people  at  risk  of  developing  MDD,  identify  genetic  and environmental  factors  that  lead  from  risk/vulnerability  to  illness,  or  select  a treatment plan, which can be preventive or after manifestation of the illness, based on each individual’s likelihood of remission. If such tools were developed, they could significantly  reduce  the  morbidity  and  mortality  resulting  from  ineffective treatment trials (Leuchter et al., 2010; Taylor et al., 2005).  Consequently,  there  is  a  critical  need  to  both  identify  biologic  traits  (i.e. biomarkers)  that objectively  characterize  a  specific population with  respect  to HC (e.g. MDD, MDD offspring), and develop automatic algorithms that, working on the information  provided  by  these  biomarkers,  help  clinicians  identify  subjects  at highest risk of MDD and consequently provide the optimal  therapy on the basis of the prediction of each individual’s response to treatment. 
In vivo brain imaging techniques such as PET, structural Magnetic Resonance Imaging (MRI),  functional MRI, Diffusion Tensor Imaging (i.e. a MRI technique that measures the restricted diffusion of water in tissue to produce neural tract images), 
Arterial Spin Labeling (i.e. a MRI technique that measures cerebral perfusion), and Electroencephalography  can  each  assess,  in  a  non‐invasive  way,  different  brain structures  and  functions,  and  have  already  provided  some  neural  predictors  of response to treatment for MDD patients (Bruder et al., 2008; Chen et al., 2007; Gong 
et al., 2011; Konarski et al., 2009; Milak et al., 2009; Siegle et al., 2006). Furthermore, so  far none has performed a multi‐modalities  investigation  in the specific case of MDD offspring. The extent to which outcome measures derived via  brain  imaging,  as  biomarkers  of  MDD,  can  classify  young  subjects  at  risk  of developing depression by virtue of being offspring of MDD probands has yet to be examined.  Therefore, on the basis of preliminary results, we aim to: • determine whether the abnormality of higher serotonin 5‐HT1A binding, which can only be assessed in vivo via PET, together with other structural biomarkers derived via MRI (e.g. cortical thickness, fractional anisotropy), can be used to automatically classify  young  subjects  at  higher  risk  for  developing  MDD  by  virtue  of  having parent(s) affected with recurrent MDD; • investigate the genetic and environmental factors that lead from risk/vulnerability to illness, and predict each individual’s likelihood of remission to specific treatments on  the  basis  of  PET,  MRI,  and  potentially  biomarkers  derived  from  other  brain imaging modalities, in order to select the optimal treatment. As depression  is  a heterogeneous and complex disorder, whose occurrence and  differential  treatment  prediction  likely  require  information  derived  from  a combination of imaging modalities, we propose the development of a technique that jointly  analyzes  data  from  multiple  imaging  modalities  in  order  to  identify biomarkers  predictive  of  high  risk  for MDD  for  early  preventive  intervention.  To achieve this, we will consider the use of advanced machine learning and data mining techniques, which have  the potentiality of enhancing  image‐derived measures and elucidating function‐structure networks (Sui et al., 2011). 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